Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients
@article{Keene2014EffectOC, title={Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients}, author={D. Keene and C. Price and Matthew J Shun-Shin and D. Francis}, journal={The BMJ}, year={2014}, volume={349} }
Objective To investigate the effects on cardiovascular outcomes of drug interventions that increase high density lipoprotein levels. Design Meta-analysis. Studies reviewed Therapeutic benefit of niacin, fibrates, and cholesteryl ester transfer protein (CETP) inhibitors on cardiovascular events (all cause mortality, coronary heart disease mortality, non-fatal myocardial infarction, and stroke). Results 117 411 patients were randomised in a total of 39 trials. All interventions increased the… CONTINUE READING
Topics from this paper
Paper Mentions
300 Citations
Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis
- Medicine
- European journal of preventive cardiology
- 2019
- 10
Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis
- Medicine
- Heart
- 2015
- 14
With statin co-administration, drugs designed to increase HDL have no impact on cardiovascular outcomes
- Medicine
- Evidence-Based Medicine
- 2014
- 1
- PDF
Statin Effects on Metabolic Profiles: Data From the PREVEND IT (Prevention of Renal and Vascular End-stage Disease Intervention Trial)
- Medicine, Biology
- Circulation. Cardiovascular genetics
- 2017
- 7
Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Medicine
- Cardiology
- 2020
- 2
Role of Niacin in Current Clinical Practice: A Systematic Review.
- Medicine
- The American journal of medicine
- 2017
- 33
High Density Lipoprotein Cholesterol Increasing Therapy: The Unmet Cardiovascular Need
- Medicine
- Translational medicine @ UniSa
- 2015
- 5
- PDF
References
SHOWING 1-10 OF 59 REFERENCES
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins
- Medicine
- Circulation
- 2004
- 721
- PDF
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
- Medicine
- Lancet
- 2005
- 2,607
- PDF
Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.
- Medicine
- European heart journal
- 2012
- 199
- PDF
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
- Medicine
- Lancet
- 2005
- 5,794
- PDF
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
- Medicine
- The New England journal of medicine
- 2012
- 1,526
- PDF
A Randomized Trial of a Strategy for Increasing High-Density Lipoprotein Cholesterol Levels: Effects on Progression of Coronary Heart Disease and Clinical Events
- Medicine
- Annals of Internal Medicine
- 2005
- 179
Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence.
- Medicine
- Journal of clinical lipidology
- 2007
- 34
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
- Medicine
- The New England journal of medicine
- 1999
- 2,929
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
- Medicine
- The New England journal of medicine
- 1987
- 3,613
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
- Medicine
- The New England journal of medicine
- 2011
- 2,215
- PDF